BioPharma Dive June 12, 2024
Delilah Alvarado

The venture firm will work with ProFound Therapeutics to “rapidly surface” protein drug candidates that Pfizer can choose to advance under a partnership it struck with Flagship last year.

Dive Brief:

  • Flagship Pioneering will partner with biotechnology startup ProFound Therapeutics to search for promising drug candidates for obesity that Pfizer, under a deal struck with Flagship last year, may later choose to advance.
  • The collaboration between Flagship and ProFound, which the venture firm founded in 2022, is the first drug-hunting effort started through the alliance Flagship and Pfizer formed in July. At the time, both Flagship and Pfizer said they would invest $50 million to develop 10 drug candidates that Pfizer would have an option to later license...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Partnerships, Pharma / Biotech, Trends
Related Articles:
Bariatric Surgeons Being Put Out of Work by GLP-1 Drugs
The CMS NHE 2023 Report: An Incomplete Picture at a Pivotal Time
Gene Therapy Shows Long-Term Vision Benefits in Rare Eye Disease
A Biologist Explains The ‘Weird’ Habits Of People Who Live To 100+ Years Old
U.S. Health Care Spending Reaches $4.9 Trillion

Share This Article